🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Danielle C. McDonald

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer”.

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.05.028
N/A
0DataRank · unranked
22 citations

Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri +10 more

Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9533
N/A
0DataRank · unranked
2 citations

Poorva Bindal, Anita G. Koshy, Ritu Gill, Danielle C. McDonald, Deepa Rangachari +2 more

Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21579
N/A
0DataRank · unranked
0 citations

Ritu R. Gill, Poorva Bindal, Anita G. Koshy, Danielle C. McDonald, Deepa Rangachari +2 more

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.37120
N/A
0DataRank · unranked
165 citations

Ritu R. Gill, Page Widick, Poorva Bindal, Danielle C. McDonald, Meghan Shea +3 more